Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Omata M., Kanda T., Yokosuka O., Crawford D., Al-Mahtab M., Wei L., ...Daha Fazla

HEPATOLOGY INTERNATIONAL, cilt.9, sa.4, ss.486-507, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 9 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s12072-015-9630-4
  • Dergi Adı: HEPATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.486-507
  • Anahtar Kelimeler: Asian Pacific countries, HCV, IL28B, Direct-acting antivirals, SUSTAINED VIROLOGICAL RESPONSE, RANDOMIZED CONTROLLED-TRIAL, HEALTH-CARE WORKERS, INTERFERON-ALPHA-2B PLUS RIBAVIRIN, TREATMENT-EXPERIENCED PATIENTS, TREATMENT-NAIVE PATIENTS, CHRONIC LIVER-DISEASES, CHRONIC-RENAL-FAILURE, LONG-TERM EFFICACY, CHRONIC GENOTYPE 2
  • Ankara Üniversitesi Adresli: Evet

Özet

Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-1.0, 14.7, 0.1-0.3, 0.9-1.9, 1.0-2.0, 5, 4.4-8.6 and 0.5-1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are similar to 50 % in Australia and Turkey, but 60-70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.